I think we've mentioned before that the meaning of this biosimilar product for Teva is just that it's their first BLA application in the US. Other branded generic versions of G-CSF, which have been launched in the EU also have had very limited commercial success (like you said, they aren't interchangeable plus Amgen gave them a fight reducing prices).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.